Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 3:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 37 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetic Macular Edema (DME)
Interventions
Tabirafusp tedromer, Aflibercept (2.0 mg)
Drug
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Glendale, California • Pasadena, California • St. Petersburg, Florida + 6 more
Conditions
Diabetic Macular Edema
Interventions
intravitreous aflibercept, Bevacizumab + Deferred Aflibercept Group
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
54
States / cities
Campbell, California • Glendale, California • Loma Linda, California + 46 more
Conditions
AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)
Interventions
Alfilbercept
Drug
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Choroidal Neovascularization, Presumed Ocular Histoplasmosis
Interventions
EYLEA (Aflibercept) intravitreal injection
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
21 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
St Louis, Missouri
Conditions
Diabetic Macular Edema
Interventions
2.0 mg intravitreal aflibercept, 1.25 mg intravitreal bevacizumab, 0.3 mg intravitreal ranibizumab
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
90
States / cities
Tucson, Arizona • Beverly Hills, California • Loma Linda, California + 72 more
Conditions
Diabetic Macular Edema
Interventions
Aflibercept, OPT-302, Sham intravitreal injection
Biological · Other
Lead sponsor
Opthea Limited
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
34
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 31 more
Conditions
Macular Degeneration
Interventions
VEGF Trap
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
8
States / cities
Tuscon, Arizona • Loma Linda, California • Chicago, Illinois + 5 more
Conditions
Neovascular Age-related Macular Degeneration
Interventions
0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
Biological
Lead sponsor
Chengdu Kanghong Biotech Co., Ltd.
Industry
Eligibility
50 Years and older
Enrollment
1,157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
Conditions
Central Retinal Vein Occlusion
Interventions
aflibercept, bevacizumab
Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Mountain View, California + 60 more
Conditions
Macular Edema, Retinal Artery Macroaneurysm
Interventions
aflibercept
Drug
Lead sponsor
Kamal Kishore, MD
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Peoria, Illinois
Conditions
Wet Age Related Macular Degeneration, wAMD
Interventions
EYP-1901, Aflibercept (2.0 mg)
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
78
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 69 more
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Interventions
ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more
Conditions
Diabetic Retinopathy
Interventions
670nm PBM, intravitreous VEGF-inhibitors
Device · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin